Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KMO | O15229 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | BCR | P11274 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | RXRB | P28702 | 2/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17125388 | 0.89 | MEN1 (0.52) | MEN1NPC1RAB9AKMT2AKMO | |
| SCHEMBL2709538 | 0.87 | RXRA (0.45) | MEN1NPC1RAB9AKMT2AABL1 | |
| SCHEMBL182353 | 0.85 | NPC1 (0.60) | MEN1NPC1RAB9AKMT2AKMO | |
| SCHEMBL182222 | 0.81 | MEN1 (0.69) | MEN1NPC1RAB9AKMT2AKMO | |
| SCHEMBL182403 | 0.80 | MEN1 (0.61) | MEN1NPC1RAB9AKMT2AKMO | |
| SCHEMBL182131 | 0.79 | MEN1 (0.54) | MEN1NPC1RAB9AKMT2AKMO | |
| SCHEMBL17125400 | 0.77 | NPC1 (0.49) | MEN1NPC1RAB9AKMT2AKMO | |
| SCHEMBL2708195 | 0.77 | NPC1 (0.60) | MEN1NPC1RAB9AKMT2AKMO | |
| SCHEMBL182457 | 0.77 | NPC1 (0.57) | MEN1NPC1RAB9AKMT2AKMO | |
| SCHEMBL182482 | 0.77 | NPC1 (0.63) | MEN1NPC1RAB9AKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150274674-A1 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | PTC THERAPEUTICS, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150274674-A1 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | PTC THERAPEUTICS, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-9051342-B2 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation related diseases | PTC THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051342-B2 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation related diseases | PTC THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| EP-2402323-A2 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases | PTC Therapeutics, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2387995-A1 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC Therapeutics, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| EP-2363129-A1 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases | PTC Therapeutics, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| EP-2316452-A1 | Pyrrol derivatives, uses thereof | PTC Therapeutics, Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20080280869-A1 | Pyrazole or Triazole Compounds and Their Use for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | PTC THERAPEUTICS, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280869-A1 | Pyrazole or Triazole Compounds and Their Use for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | PTC THERAPEUTICS, INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2007117438-A2 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | UPF1, DNAJC10, RNGTT | MEN1 3100/4885NPC1 2442/4885RAB9A 2451/4885 |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | UPF1, DNAJC10, RNGTT | MEN1 2786/4885NPC1 2269/4885RAB9A 2860/4885 |
| US-20080280869-A1 | Pyrazole or Triazole Compounds and Their Use for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | UPF1, RNMT, VHL | MEN1 3684/4885NPC1 1560/4885RAB9A 3615/4885 |
| US-20150274674-A1 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | UPF1, RNMT, VHL | MEN1 3684/4885NPC1 1560/4885RAB9A 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.